title: Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition.
abstract: BACKGROUND
  Although there is evidence of metabolic risks in young women with irregular menses and androgen excess, persistence of risks after menopause is unclear.
  
  
  OBJECTIVE
  The objective of the study was to determine the impact of menopause on the cardiometabolic profile in women with high androgens and a history of menstrual irregularity.
  
  
  METHODS
  Study of Women's Health Across the Nation is a longitudinal cohort study. Data from 1929 women without metabolic syndrome (MetS) at baseline were analyzed for incidence of MetS, self-reported stroke, and myocardial infarction. Cox hazard ratios (HRs) were estimated, adjusting for age, ethnicity, body mass, smoking, menopausal status, and study site.
  
  
  RESULTS
  Among MetS-free women at baseline, 497 new cases were identified during 20 249 woman-years of follow-up over 12 years. Women with hyperandrogenemia (HA) and oligomenorrhea (Oligo) developed incident cases of MetS at a comparable rate compared with their counterparts: eumenorrheic, normoandrogenic women [HR 1.4 (0.9-2.2)], oligomenorrheic, normoandrogenic women [HR 1.3 (0.8-2.2)], and eumenorrheic hyperandrogenic women [HR 1.2 (0.7-1.8)]. Smoking and obesity were the strongest predictors of incident MetS. There was no significant difference in incidence of self-reported stroke or MI by HA/Oligo status.
  
  
  CONCLUSIONS
  Longitudinal evidence suggests that a history of androgen excess and menstrual irregularity is not associated with worsening of metabolic health after menopause. Our findings challenge the notion that a history of concurrent HA and Oligo reflects ongoing cardiometabolic risk in postmenopausal women.
authors: Department of Obstetrics and Gynecology (A.J.P., A.A.A., N.S.), University of Colorado Denver, and Department of Biostatistics and Informatics (A.A.A.), School of Public Health, University of Colorado Denver, Aurora, Colorado 80045; Department of Epidemiology, Preventive, and Behavioral Medicine (S.L.C.), University of Massachusetts Medical School, Worcester, Massachusetts 01655; School of Public Health (S.D.H.), University of Michigan, Ann Arbor, Michigan 48109; Department of Community Health (N.K.), Boonshoft School of Medicine, Wright State University, Dayton, Ohio 45420; Department of Endocrinology and Preventive Cardiology (R.K.), Rush University, Chicago, Illinois 60612; and Department of Obstetrics and Gynecology (R.S.L.), Penn State College of Medicine, Hershey, Pennsylvania 17033.
authors: Alex J
authors: AJ
authors: Polotsky
authors: Amanda A
authors: AA
authors: Allshouse
authors: Sybil L
authors: SL
authors: Crawford
authors: Sioban D
authors: SD
authors: Harlow
authors: Naila
authors: N
authors: Khalil
authors: Rasa
authors: R
authors: Kazlauskaite
authors: Nanette
authors: N
authors: Santoro
authors: Richard S
authors: RS
authors: Legro
mesh_terms: D000728:Androgens / Q000097:blood; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000453:epidemiology* / Q000378:metabolism*; D015994:Incidence; D008137:Longitudinal Studies; D008593:Menopause; D024821:Metabolic Syndrome / Q000453:epidemiology*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000453:epidemiology; D009839:Oligomenorrhea / Q000453:epidemiology* / Q000378:metabolism*; D012307:Risk Factors; D020521:Stroke / Q000150:complications / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
chemical_list: D000728:Androgens